Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...
Zacks.com on MSN7h
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded UseAstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the ...
AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...
On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...
AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...
LouderSound on MSN2d
"This miraculous turnaround": Mike Peters' cancer is in remission thanks to a revolutionary drug trialDiagnosed with leukaemia nearly three decades ago, The Alarm's Mike Peters is now hopeful of "a way to be cured once and for ...
Mike Peters, frontman of Welsh band The Alarm, is in remission from an aggressive cancer after taking part in an experimental ...
The dad-of-two, from Dyserth, North Wales, took part in a Richter’s syndrome trial at the Christie hospital in Manchester, ...
Acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia: a meta-analysis of randomized controlled trials. J Immunother Precis Oncol. 2021;5(2):43-47. doi:10.36401 ...
The Independent on MSN3d
Rock star in remission from aggressive cancer thanks to NHS trial hopes to tour againThere, he agreed to take part in a randomised phase II clinical trial investigating the combination of a targeted therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback